PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/650,417
Filing Date	8/27/2003
First Named Inventor	Bertino et al.
Art Unit	~~1645~~ 1652
Examiner Name	
Attorney Docket Number	MSK.P-007-DV

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]- Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JCS		WO 94/24277	10/27/1994	Sloan-Kettering Inst For Cancer Research		
JCS		WO 97/33988	9/18/1997	Sloan-Kettering Inst. For Cancer Research		

Examiner Signature	T. Saidha	Date Considered	12/7/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete If Known	
Application Number	10/650,417
Filing Date	8/27/2003
First Named Inventor	Bertino et al.
Art Unit	~~1645~~ 1652
Examiner Name	
Attorney Docket Number	MSK.P-007-DV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JG		BANERJEE ET AL., Transfection with a cDNA encoding a Ser^{31} or Ser^{34} mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance, Gene, 1994 , Page(s) 269-274, Volume 139	
		BANERJEE ET AL., Molecular mechanisms of resistance to antifolates, A review, Acta Biochimica Polonica, 1995, Page(s) 457-464, Volume 42, Number 4	
		DICKER ET AL., Identification and Characterization of a Mutation in the Dihydrofolate Reductase Gene from the Methotrexate-resistant Chinese hamster ovary cell line Pro^{-3} Mtx^{RIII}, The Journal of Biological Chemistry, May 15, 1990 , Page(s) 8317-8321, Volume 265, Number 14	
		FAN ET AL., Demonstration of Rb-mediated drug sensitivity and growth inhibition by an inducible expression system, AACR Abstract Form, 1995	
		HUANG ET AL., Nonadditivity of Mutational Effects at the Folate Binding Site of *Escherichia coli* Dihydrofolate Reductase, Biochemistry, 1994 , Page(s) 11576-11585, Volume 33	
		LI ET AL., Development of a Retroviral Construct Containing a Human Mutated Dihydrofolate Reductase cDNA for Hematopoietic Stem Cell Transduction, Blood, June 1, 1994, Page(s) 3403-3408, Volume 83, Number 11	
		ROSOWSKY ET AL., 2,4-Diamino-5-substituted-quinaxolines as Inhibitors of a Human Dihydrofolate Reductase with a Site-Directed Mutation at position 22 and of the dihydrofolate reductases from *Pneumocystis carinii* and *Toxoplasma gondii*, J. Med. Chem., 1995, Page(s) 745-752, Volume 38	
		SCHWEITZER ET AL., Mutations at Hydrophobic Residues in Dihydrofolate Reductase. In: Chemistry and Biology of Pteridines 1989, Pteridines and Folic Acid Derivatives, Proceedings of the Ninth International Symposium on Pteridines and Folic Acid Derivatives Chemical, Biological and Clinical Aspects, Zurich, Switzerland 1989, Page(s) 760-764. Sep. 3-8, 1989, Edited by H.-Ch. Curtis, S. Chisla and N. Blau	
		SCHWEITZER ET AL., Mutations in the Human Dihydrofolate Reductase In: Chemistry and Biology of Pteridines, Pteridines and Folic Acid Derivatives, 1986, Proceedings of the Eighth International Symposium on Pteridines and Folic Acid Derivatives Chemical, Biological and Clinical Aspects, Montreal Canada. June 15-20, 1986, Page(s) 793-797. Edited by: B.A. Cooper and V.M. Whitehead	
JG		SCHWEITZER ET AL., Probing the Role of Two Hydrophobic Active Site Residues in the Human Dihydrofolate Reductase by Site-Directed Mutagenesis, J. Biol. Chem., December 5, 1989, Vol. 264, No. 34, Page(s) 20786-20795.	

Examiner Signature	T. Saidha	Date Considered	12/7/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.